(Q39666393)

English

Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8(+) T cells against prostate cancer cells and defined prostate cancer-specific epitopes

scientific article published on 17 August 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 September 2017

Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8(+) T cells against prostate cancer cells and defined prostate cancer-specific epitopes (English)

1 reference

Europe PubMed Central

PMC publication ID

13 September 2017

apoptotic process

0 references

prostate cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Robbie B. Mailliard

3

1 reference

Europe PubMed Central

PMC publication ID

13 September 2017

Jacques Banchereau

6

object named as

Jacques Banchereau

1 reference

Europe PubMed Central

PMC publication ID

13 September 2017

author name string

Eva Wieckowski

1

1 reference

Europe PubMed Central

PMC publication ID

13 September 2017

Gurkamal S Chatta

2

1 reference

Europe PubMed Central

PMC publication ID

13 September 2017

William Gooding

4

1 reference

Europe PubMed Central

PMC publication ID

13 September 2017

Karolina Palucka

5

1 reference

Europe PubMed Central

PMC publication ID

13 September 2017

Pawel Kalinski

7

1 reference

Europe PubMed Central

PMC publication ID

13 September 2017

publication date

17 August 2010

1 reference

Europe PubMed Central

PMC publication ID

13 September 2017

1 reference

Europe PubMed Central

PMC publication ID

13 September 2017

71

1 reference

Europe PubMed Central

PMC publication ID

13 September 2017

2

1 reference

Europe PubMed Central

PMC publication ID

13 September 2017

125-133

1 reference

Europe PubMed Central

PMC publication ID

13 September 2017

Whole-cell vaccines: A failure or a success waiting to happen?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2989344

14 September 2017

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2989344

14 September 2017

Independent regulation of chemokine responsiveness and cytolytic function versus CD8+ T cell expansion by dendritic cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2989344

14 September 2017

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2989344

14 September 2017

Cancer statistics, 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2989344

14 September 2017

Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2989344

14 September 2017

Memory CD8+ T cells protect dendritic cells from CTL killing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2989344

14 September 2017

Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2989344

14 September 2017

Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2989344

14 September 2017

Sipuleucel-T (APC8015) for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2989344

14 September 2017

Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2989344

14 September 2017

Tumor escape mechanisms in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2989344

14 September 2017

Cancer statistics, 2005

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2989344

14 September 2017

Androgen deprivation therapy for prostate cancer: current status and future prospects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2989344

14 September 2017

Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2989344

14 September 2017

A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2989344

14 September 2017

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2989344

14 September 2017

Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2989344

14 September 2017

Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2989344

14 September 2017

Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2989344

14 September 2017

Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2989344

25 September 2017

Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2989344

25 September 2017

In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2989344

25 September 2017

Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2989344

17 June 2018

Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2989344

17 June 2018

Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2989344

17 June 2018

Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2989344

17 June 2018

Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2989344

21 August 2018

Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20717900

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20717900

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides

1 reference

https://pubmed.ncbi.nlm.nih.gov/20717900

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20717900

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/20717900

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20717900

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction

1 reference

https://pubmed.ncbi.nlm.nih.gov/20717900

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/20717900

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human prostate cancer blocks the generation of dendritic cells from CD34+ hematopoietic progenitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/20717900

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dendritic cell-based treatment of cancer: closing in on a cellular therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20717900

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/20717900

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20717900

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/20717900

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/PROS.21228

1 reference

Europe PubMed Central

PMC publication ID

13 September 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39666393&oldid=1852821226"